Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Introduction Plasma biomarkers of Alzheimer's disease (AD) represent accessible alternatives to positron emission tomography (PET) and cerebrospinal fluid (CSF)-based biomarkers in well-characterized cohorts. It remains to be determined whether performance is maintained in outpatient clinics comprised of patients with multiple causes of cognitive impairment. Methods Plasma phosphorylated tau217 (p-tau217) and amyloid beta (Aβ) 42/40 were measured in 509 patients evaluated in a tertiary-care memory clinic. Biomarker performance was compared across diagnoses, referencing established cutpoints for positive and negative biomarkers. Results Plasma p-tau217 distinguished patients with diagnoses of symptomatic AD with 95% sensitivity and 82% specificity. Integration of Aβ42 measurements (p-tau217/Aβ42) incrementally improved specificity (86%). Plasma p-tau217 and p-tau217/Aβ42 concentrations closely associated with established CSF biomarkers of AD (area under the curve [AUC]: 0.94 and 0.96, respectively). Reduced kidney function associated with elevated plasma p-tau217 and p-tau217/Aβ42 concentrations in patients without AD (referencing CSF biomarkers). Discussion Plasma p-tau217 and p-tau217/Aβ42 concentrations demonstrated robust diagnostic performance in a heterogeneous clinical cohort; interpretation requires consideration of kidney function. Highlights Plasma phosphorylated tau217 (p-tau217) reliably identified clinic patients with Alzheimer's disease. A two-cutpoint strategy yielded definitive results in 86% of patients. Integration of plasma amyloid beta (Aβ; p-tau217/Aβ42) minimally improved diagnostic performance. Plasma p-tau217 levels were increased in patients with kidney dysfunction.

What this study adds

Evidence grade: Moderate

This is a cross-sectional study of 509 participants. In 509 patients at a tertiary-care memory clinic, plasma p-tau217 distinguished symptomatic Alzheimer's disease with 95% sensitivity and 82% specificity, and adding Aβ42 improved specificity to 86%. Reported effect size: Sensitivity 95%, specificity 82% (86% with Aβ42 ratio) for symptomatic AD.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Piura, Y. D., Figdore, D. J., Lachner, C., Bornhorst, J., Algeciras-Schimnich, A., Graff-Radford, N. R., et al. (2025). Diagnostic performance of plasma p-tau217 and Aβ42/40 biomarkers in the outpatient memory clinic. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70316

Vancouver

Piura YD, Figdore DJ, Lachner C, Bornhorst J, Algeciras-Schimnich A, Graff-Radford NR, et al. Diagnostic performance of plasma p-tau217 and Aβ42/40 biomarkers in the outpatient memory clinic. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70316. PMID: 40476540.

BibTeX

@article{piura2025-40476540,
  author  = {Piura, Y. D. and Figdore, D. J. and Lachner, C. and Bornhorst, J. and Algeciras-Schimnich, A. and Graff-Radford, N. R. and Day, G. S.},
  title   = {{Diagnostic performance of plasma p-tau217 and Aβ42/40 biomarkers in the outpatient memory clinic}},
  journal = {Alzheimer's \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.70316},
  pmid    = {40476540},
  url     = {https://doi.org/10.1002/alz.70316}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

In 509 patients at a tertiary-care memory clinic, plasma p-tau217 distinguished symptomatic Alzheimer's disease with 95% sensitivity and 82% specificity, and adding Aβ42 improved specificity to 86%. The study also found that reduced kidney function was associated with elevated plasma p-tau217 and p-tau217/Aβ42 concentrations in patients without Alzheimer's disease, so interpretation requires consideration of kidney function.

Study details

Limitations

Most patients were non-Hispanic White, so evaluation in representative cohorts with more Black and Hispanic patients is needed; the academic referral centre's expertise in normal-pressure hydrocephalus likely over-represented that diagnosis compared with community practice.

How this study scored 62/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 4 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 2 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 2 of 6; Still being cited 2 of 4; Senior author's track record 2 of 4; Institution's track record 2 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read left out, no data. 61 of the 98 points it could be judged on, which is 62 of 100. Total 62 of 100.61 of the 98 points we could judge = 62 of 100

Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 61 of the 98 points we could judge it on, which is 62 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Alzheimer's & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 4 / 12 A snapshot of people at one point in time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 2 / 4 509 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 30 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 10.0 citations a year over 3 year(s) since 2025
Impact for its field and year 4 / 6 Cited 19.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 5 other studies in this library
Still being cited 2 / 4 Cited 30 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Gregory Scott Day: h-index 43 (OpenAlex, whole career)
Institution's track record 2 / 3 Mayo Clinic: institution h-index 1,606 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40476540)
Free to read — / 2 Access not recorded — left out of this score
Points 61 / 98 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 61 of the 98 points we could judge it on is 62 out of 100.
Total 62 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 31.

Later studies that cite this one

5 studies in the alzhub library list this one in their references.

Related studies in Biomarkers from nearby years

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →